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Abstract

Introduction
The purpose of this study was to compare dose to organs at risk as well as PTV coverage.
Physical objectives, biological objectives, and a combination of the two were utilized to compare
which technique provided the best coverage of the PTV while also preserving the greatest
amount of healthy tissue.
Methods
Each randomly selected patient had three separate plans created for them. The first plan
used only physical based constraints in the form of upper objectives. The second plan used only
biological based constraints in the form of gEUD objectives. The third plan used a combination
of both upper and gEUD based objectives.
Results
Results indicate a there was a difference to plan quality when using both uppers and
gEUD based objectives. In regard to organs at risk, a physical upper constraint of 0% of the
organ volume receiving a maximum dose, as well as a gEUD constraint with an alpha value of 1
provided the most optimal plans. A low priority value on the gEUD (60-70) in conjunction with
the upper value provided a gentle, yet effective way to control dose to nearby organs at risk
without resulting in suboptimal dose to planning target volume.
Conclusion
A combination of upper values and gEUD objectives provided lowest dose to organs at
risk while maintaining a desired dose to PTV coverage. For further success, it was recommended
that the organs at risk be cropped out of the PTV in order do provide the lowest dose as
reasonably achievable in that organ, while not influencing coverage of the PTV itself.
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Introduction
In the year 2021, the American Cancer Society estimates that 60,430 new cases of
pancreatic cancer will be diagnosed1. Out of these newly diagnosed patients, the predicted deaths
from this malignancy are projected to be nearly 48,220 representing an unfavorable prognosis1.
Pancreatic cancer accounts for 2-3% of all cancers in the United States today1. It occurs more
frequently in men than women with the average age ranging from 50-80 years old2.
Risk Factors
Certain risk factors attributable to pancreatic carcinoma include cigarette smoking which
is thought to cause 20% of cases2. Other risk factors include exposure to chemicals, chronic
pancreatitis, certain types of familial breast cancer, colorectal cancer as well as family history of
pancreatitis2. Diets rich in fat, red and processed meats, lack of physical activity as well as
obesity have also been found to increase the risk of this diagnosis2. Those with type 2 diabetes
are at a higher risk for pancreatic cancer as well1.
Anatomy
The pancreas lies across the upper abdomen and posterior to the stomach at the vertebral
levels of L1-L23. It is divided into three areas including the head, body and tail2. The head resides
in the C shaped loop of the duodenum which is the first segment of the small bowel2. The body
of the pancreas sits posterior to the stomach while the tail hugs the hilum of the spleen2.

3

Treatment Information
Surgery is the optimal treatment for pancreatic cancer2. Although at presentation most
tumors are unresectable due to local invasion of critical structures such as the small bowel,
stomach and colon leaving radiation therapy as a viable option2. If surgery is possible, the
Whipple procedure is the most commonly performed2.
Radiation in conjunction with chemotherapy is the main stay of treatment for patients who
present with locally advanced, unresectable tumors2. High doses of radiation to the tumor bed
and target volume may contribute to an increase in survival rates and local control of the
disease2.
One technique used to deliver adequate dose to the PTV is conformal 3D treatment
planning often called 3DCT2. This is a traditional approach in which dose conformality around
the target volume is achieved by the use of a combination of static beams (4-6) which enter at
unique angles2.
A technique gaining popularity is intensity modulated radiation therapy (IMRT) or
volumetric arc therapy (VMAT). In this technique, the beam intensity and field shape is
modulated with the use of multileaf collimators (MLC’s) 2. These MLCs act as individual leaves
that shape the field helping deliver dose to the PTV and spare the surrounding OARs of
unnecessary dose. The advantage of IMRT/VMAT over 3DCRT is a reduction in dose to nearby
OARs such as the kidneys, bowel and liver and a more conformal dose distribution surrounding
the PTV through the use of optimization techniques.

4

Optimization
When using an IMRT/VMAT planning technique, optimization is required to modulate
dose to tissue. The goal is to achieve a high likelihood of local tumor control termed tumor control
probability (TCP), as well as a decreased risk of normal tissue complication often referred to as
NTCP6. Objectives are utilized in the optimization of treatment planning to specify acceptable
dose to various anatomical structures. These objectives can be used in many different combinations
to obtain a treatment plan with optimal dose to the planning target volume as well as the nearby
organs at risk. Reduced dose to organs at risk decreases the likelihood of later complications in
functionality of the structure.
Physical Optimization
Physical optimization is DVH based in which dose constraints are outlined with the
tolerance doses defined by QUANTEC. With the use of functions termed uppers and lowers, the
treatment planner can set maximum and minimum dose constraints to the PTV and OARs. For
example, an upper constraint tells the TPS the 0% of the GTV can receive no more than 105% of
the total dose. A lower constraint tells the TPS that 100% of the PTV must receive at least
95%100% of the total treatment dose. Mean dose to the structure is an additional parameter that
may be set in the optimizer. A priority value is also utilized to tell the optimizer how hard to
work on a given objective set by the treatment planner.
Biological Optimization
Biological optimization differs from physical optimization in that gEUD parameters are
utilized in place of upper constraints. The Varian Eclipse treatment planning software (TPS)
database describes the gEUD as “the uniform dose distribution that gives a biological effect
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equivalent to that of a given heterogeneous dose distribution” 7. This technique aims to provide
the same type of tumor response achieved by physical constraints, while at the same time
attempting to lower the dose that healthy tissue receives from ionizing radiation.
Literature Review
A comparable study was performed by Dirscherl et al. regarding physical versus biologic
optimization in prostate cancer planning8. Plans were compared using physical dose volume
objectives on one plan and only biologic based constraints on the other8. Beam angles, number of
beams as well as dose all remained the same8. Results show a “small and negative value”
resulted in a plan with inhomogeneity of dose as well as hot and cold spots withing the TV8.
Sparing of OARs proved more favorable with use of gEUD although dose to the PTV
decreased8. The study proved bladder and rectum sparing greatly depend on the α value used.

Sakthivel et al. also compared this technique in 10 treatment plans in the case of
hypopharyngeal tumors9. All parameters were kept the same besides optimization techniques and
values9. The results show comparable plan quality regarding dose to the PTV although the
biological based optimization plan revealed greater OAR sparing for serial structures (in this
case the brainstem and spinal cord) 9. The physical based optimization plan showed better OAR
sparing for parallel structures such as the parotid glands9. The overall treatment time was also
more favorable in the biological based optimization plan9. Although, the research proved further
investigation into the variety of α values available is needed to obtain greater understanding of
how to secure the greatest amount of OAR sparing9.
D Mihailidis et al. investigated which plan proved superior in regard to head and neck
planning as well as chest wall treatment plans when using gEUD versus DVH based
6

constraints10. 10 plans were compared, and the results showed the gEUD based plans allow for
an increase of dose sparing to OARs while the PTV coverage remained optimal10. The ipsilateral
lung V20 was reduced from 22% to 18% for the gEUD plan10. This shows a 1.2% improvement
for dose to lung volume. Dose to all OARs decreased, even below the constraint
recommendation10.
Dogan similarly compared head and neck plans using Pinnacle. Physical DVH based
objectives were used as well as gEUD based objectives11. The gEUD based plan resulted in
reduced spinal cord dose by 55%, 14% reduction in brainstem dose as well as a 35% reduction in
parotid gland dose11. Dogan utilized various α values (1, 5, 10) and in doing so noticed an
increase in monitor units (MU) by 12%, 19%, and 21% 11.
Fogliata et al. analyzed the performance and effectiveness of gEUD parameters in OAR
sparing in the photon optimizer (PO) of the Varian Eclipse TPS12. The treatment plans included
head and neck, prostate, rectum and one parotid carcinoma plan12. The OARs were placed at
variable distances (4mm, 1 cm, 2 cm) and cropped (0mm, 2mm, 4mm) from the target and
evaluated12. The α value was varied from 1-40 to assess the effectiveness of said variable12. The
findings revealed a reduction in OAR dose when the OAR was within 1-2 cm distance from the
TV along with an increase in α values12. The ideal α value was dependent upon the distance from
the target as well as seriality of the OAR12. The α parameters in the conjunction with OAR
sparing needs to be investigated further12.
Purpose of Study
While research has been performed comparing biologic and physical based
optimization strategies, there has yet to be a quantitative study on how varying α values (1 and
7

40) within the biologic optimization compares to physical based DVH optimization. This
research aims to provide a quantitative investigation into the PTV coverage as well as dose at
various volumes when using physical versus biological optimization strategies with a variation in
α parameters. A question that remains unanswered is does a physical or biological based
optimization strategy provide a more favorable quality plan in regard to PTV coverage and OAR
dose in pancreatic treatment plans. A hypothesis that may be assumed from prior research is that
the use of gEUD will provide a more favorable dose to critical structures than physical based
objectives.

Methods and Materials
Patient Selection

This was a retrospective study of 15 male and female patients previously treated for
locally advanced pancreatic carcinoma. These patients were treated using a volumetric
modulated arc therapy (VMAT) technique at the Memorial Sloan Kettering Cancer Center. The
patients were chosen at random using the Cancer Imaging Archive (TCIA) which de-identified
patient information and hosts cancer imaging data online.
The researcher submitted a research determination form to the Office of Research
Compliance & Integrity. It was determined that the project did not meet the definition of human
subjects due to the fact that no private or identifiable information had been utilized. Therefore, it
did not meet the federal definition of human subjects and subsequently IRB oversight was not
needed.
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Simulation
A common technique was utilized to simulate the patient in the supine position with the
arms above the head with the help of a wing board. This ensured the arms were out of the
treatment field and the wing board aided in reproducibility of the positioning. Oral contrast may
be used to better visualize the duodenum while intravenous contrast can help better delineate the
target volume4. Breathing motion can influence the positioning of the pancreas. To account for
this the use of 4-dimensional computed tomography (4DCT) was implemented. Tumor and organ
motion was visualized on a computer during simulation utilizing this technique. For this study,
each patient had one treatment planning CT and two CBCT scans. They were acquired using a
deep inspiration breath hold (DIBH) which was then verified by using an external respiratory
monitoring device. The planning CT was obtained with a diagnostic quality scanner in helical
mode with iodinated contrast.
Planning
A volume of interest (VOI) was drawn on the planning CT and a margin of 1cm was
added. This VOI or target volume (TV) includes the gross tumor volume (GTV) which can be
described as the gross palpable disease that can be visualized on diagnostic imaging, as well as
any lymph nodes suspected of involvement4. Also included is the clinical target volume (CTV)
which is the GTV in addition to a 1-2 cm margin to account for any possible microscopic disease
spread4. Further, a planning target volume (PTV) margin is included to account for any
uncertainties in patient set up error or patient movement during treatment4. This margin can be
anywhere from .5 mm if 4DCT is utilized up to 1 cm4. The organs at risk (OARs) were
delineated by the same physician for continuity purposes including the stomach and small bowel.
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The additional OARs were contoured by the same planner, again, for continuities sake. These
OARs included large bowel, lungs and kidneys and were reviewed by the researcher.
Each patient was planned utilizing a 2-arc VMAT technique with 6MV beam energy. The
full arcs rotated from 181-179 degrees around the patient. The collimator was rotated to
encompass the shape of the VOI also termed planning target volume (PTV). A complimentary
collimator angle was used for the 2nd arc. Jaw tracking was utilized for each plan. The multileaf
collimator (MLC) was fitted to the PTV with a .5cm margin. The PTV was given a dose of 4500
cGy broken down to 180cGy daily in 25 fractions. Each plan was created using the Varian
Eclipse Treatment Planning Software with the Photon Optimizer version 15.6.05 and the
Anisotropic Analytical Algorithm for all calculations. After all initial setup fields and gantry
angles were established, the plan was then copied and pasted to duplicate the exact same
parameters for a true comparison.
Three plans were created for each patient. The first plan utilized physical constraints with
only upper objectives. The second plan used only biological gEUD constraints with alpha values
of 1 and 40. The third plan used a combination of physical and biological constraints.
The physical plan utilized constraints based on certain points on the dose volume
histogram (DVH). A lower constraint defined the minimum dose the structure should receive
while an upper constraint defined maximum dose the structure can receive. The physical plan
had a lower constraint on the PTV of 100% of the structure receiving 4500 cGy with a priority of
125. The upper constraint had 0% of the PTV receiving 105% dose being 4725 cGy with a
priority of 125. Two upper constraints were then added to all applicable OARs. The upper
constraints were defined at a volume of 0% and 50% of the structure to limit unnecessary dose.
10

Two upper gEUDs were utilized for the biological plan. The upper gEUD defines the
maximum equivalent uniform dose value that a structure (target structure or OAR) may receive7.
A value of critical importance is referred to as the α value. This value represents the specific area
on the DVH the optimizer will focus on regarding dose limits. The α value ranges from -40 to
407. Negative α values will work on the low dose section on the DVH while positive values will
focus on the high dose area7. The gEUD uppers were given to all applicable OARs. The alpha
values used were 1 (aiming to control the mean dose) and 40 (aiming to control max dose).
GEUD objectives prove to be very powerful and have a large impact on the dose an organ
receives.
The third plan used a combination of the previous two techniques. The optimization
values for the PTV remained the same, while the values for the OARs were changed. The OARs
had an upper constraint with 0% of the structure receiving no more than the prescription dose if
the OAR was located inside the PTV. If the OAR was not inside the PTV the constraint was set
to limit the dose as low as reasonably achievable. An upper gEUD with an alpha value of 1 was
used to control the mean dose to the structure.
After calculation was completed, the plans were then normalized so that 100% of the dose
covered 95% of the structure. This was done to ensure the coverage intended was identical
between all 3 treatment planning techniques. The dose volume histogram (DVH) was utilized in
evaluating dose to critical structures. There are strict constraints that must be adhered to during
the treatment planning process. These constraints limit the amount of dose a structure can receive
to decrease the likelihood of long-term complications. The following constraints are summarized
by Quantitative Analyses of Normal Tissue Effects in the Clinic (QUANTEC) and Emami et al:

11

Tolerance of Normal Tissue to Therapeutic Irradiation: for the bilateral whole kidneys a mean
dose of less than 1500-1800 cGy to decrease likelihood of renal dysfunction5. Specific points on
the dose volume histogram (DVH), which provides a plot of target volumes and cumulative dose
the structures receive, are of key importance as well2. The volume receiving 12 Gy must be less
than 55% (V12 <55). Further, V20 <32%, V23 <30%, V28 <20%5. The Stomach has a constraint
of D100 <45 to avoid ulceration and must receive a max dose of less than 4500 cGy5. The liver
must receive a mean dose of less than 3000-3200 cGy to decrease the likelihood of classic
radiation induced liver disease5. The small bowel individual loops V15<120cc, entire potential
space within peritoneal cavity V45 <195cc, V50 <5%, with a max dose of less than 5000 cGy to
reduce acute toxicity5. The spinal cord max dose is 4500 cGy to decrease likelihood of
myelopathy5.
Data Analysis
Statistical analysis was performed by the Grand Valley State University statistic
counseling center using the IBM SPSS program, version 24. A one way repeated measures
ANOVA test was used for the initial testing. If the results proved to be significant, a post hoc
statistical analysis was then performed. A t-test was used to evaluate the difference between three
dependent means in the form of matched pairs with an effect size of 0.8. The matched paired ttest is used when the data from three groups can be shown in pairs. Before and after observations
can be made on the same subjects. The effect size is the magnitude of the difference between
groups. The assumptions that must be met to use this test require the dependent variable must be
continuous, the observations must be independent of each other, the dependent variable must be
normally distributed and should not contain any outliers.
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Results
This studies research aimed to provide a look at dose to multiple structures. PTV
coverage as well as dose to nearby organs at risk were evaluated when using physical, biological,
and a combination of both optimization techniques. The plan resulting in the greatest amount of
PTV coverage as well as lowest dose to critical organs was of particular interest to the
researcher. The results are indicated below.

PTV
The PTV minimum, maximum, and global dose max were evaluated for all 3 plans. The
minimum (F(2.0, 28.0) = 10.9041, p = 0.0003), maximum (F(2.0, 28.0) = 17.95, p = <0.0001),
and global dose max (F(2.0, 28.0) = 16.6472, p = <0.0001) all proved to be statistically
significant.
Mauchly’s test indicated sphericity assumed for the minimum, χ²(2.0) = 2.728, p = 0.2556.
A post hoc analysis was preformed using a paired sample t-test. The results proved the physical
plan had greater minimum coverage to the PTV (90%) compared to the biological (87%) and duo
plan (85%). See table 2.
Mauchly’s test indicated sphericity assumed for the maximum, χ²(2.0) = 5.2447, p =
0.0726. Post hoc analysis revealed the max dose was greatest with the biological plan (108%)
compared to the physical plan (106%) and duo plan (107%).
Mauchly’s test indicated sphericity assumed for the global dose max, χ²(2.0) = 4.7592, p =
0.0926. Post hoc analysis revealed the physical plan had the lowest dose max to tissue (106%)
compared to the biological plan (108%) and duo plan (107%).
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Spinal Cord
The V45 was evaluated for the spinal cord between the 3 plans. Mauchly’s test indicated
the assumption of sphericity had been met, χ²(2.0) = 1.2253, p = 0.5419. The results proved a
statistical difference between the 3 plans, F(2.0, 28.0) = 7.935, p = 0.0019. A paired sample ttest
was used to conduct a post hoc analysis of the results. Results showed the biological plan was
lower than both the physical (t(14) = 2.4, p = 0.0309) and duo (t(14) = -4.3334, p = 0.0007). The
physical plan was also lower than the duo (t(14) = -1.2061, p = 0.2478). The V45 physical mean
was 2877 cGy, the duo was 2976 cGy, with the lowest mean being the biological at 2642 cGy.
Large Bowel
The mean and max were both evaluated for the large bowel. For the mean Mauchly's test
indicated that the assumption of sphericity had been met, χ²(2.0) = 0.618, p = 0.7342. The results
show that there was a significant effect of which plan was used on the mean dose to the large
bowel, F(2.0, 28.0) = 13.5452, p = 0.0001. Therefore, the paired samples t-test was used to
conduct post hoc tests to see which of the three plans differ. The results show that duo was
significantly lower than both physical (t(14) = 4.9121, p = 0.0002) and biological (t(14) =
2.2256, p = 0.043), and biological is also significantly lower than physical(t(14) = 3.2342, p =
0.006). The mean dose for the physical plan was 1503 cGy, 1414 cGy for the biological, and
1342 cGy for the duo.
The max also proved to be statistically significant, p = 0.014. Mauchly’s test indicated
that the assumption of sphericity had been met, χ²(2.0) = 2.756, p = 0.2521. Results indicated
there was a significant effect of which plan was used on the max dose of the large bowel, F(2.0,
28.0) = 4.9937, p = 0.014. A paired samples t-test was used to conduct a post hoc test to evaluate
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the differences. The max with the biological plan was less than both the physical (t(14) = 2.5961,
p = 0.0211) and duo (t(14) = -2.2279, p = 0.0428). The duo was also less than the physical (t(14)
= 1.1534, p = 0.2681). The mean dose for the physical plan was 4177 cGy, 4125 cGy for the duo
plan, and the lowest dose being 4005 cGy for the biological plan.

Small Bowel
The mean and max were evaluated for the small bowel. For the mean results Mauchly’s
test indicated the assumption of sphericity had been met, χ²(2.0) = 2.1462, p = 0.342. The results
showed that there was a significant effect of which plan was used on the small bowel, F(2.0,
28.0) = 15.6388, p = <0.0001. Therefore, the paired samples t-test was used to conduct post hoc
analysis to see which plan differed. The results show that the duo plan was significantly lower
than both the physical (t(14) = 4.6556, p = 0.0004) and biological (t(14) = 2.0457, p = 0.0601).
The biological results were also lower than the physical (t(14) = 4.0169, p = 0.0013). The mean
dose for the physical plan was 1930 cGy, 1813 cGy for the biological, and the lowest being 1755
cGy for the duo plan. No statistical significance was shown between any of the plans for the
max, p=0.423. See table 3.
Kidneys
The V18 and mean constraints were evaluated, as well as the maximum dose received
were all evaluated for the right and left kidneys. The right kidney showed no statistical
significance for the V18 (p=0.4765) or mean (p=0.422). The max dose proved to be statistically
significant, F(2.0, 28.0) = 8.2192, p = 0.0016. Mauchly’s test indicated assumed sphericity,
χ²(2.0) = 4.5199, p = 0.1044. Post hoc analysis showed the biological plan was significantly
lower than both the physical (t(14) = 2.9765, p = 0.01) and duo (t(14) = -3.3464, p = 0.0048).
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The duo plan was also less than the physical (t(14) = 0.1432, p = 0.8881). The mean dose for the
max measure of the right kidney was 3503 cGy for the physical plan, 3422 cGy for the
biological, and the lowest dose at 3193 cGy for the biological plan.

Results showed that

the V18 and mean results were also insignificant for the left kidneys as well (p=0.3314,
p=0.3698). The max dose proved to be statistically significant, F(1.4104,
19.7463) = 3.9933, p = 0.0474. Mauchly’s test indicated a violation of sphericity assumption,
χ²(2.0) = 7.0365, p = 0.0297 so the Greenhouse- Geisser Correction factor was used, Epsilon
0.7052, F(1.4104, 19.7463) = 3.9933, p = 0.0474. A post hoc analysis was performed which
showed the biological plan was significantly lower than both the physical plan (t(14) = 2.3062, p
= 0.0369) and the duo plan (t(14) = -1.7097, p = 0.1094). The duo plan was also lower than the
physical (t(14) = 1.4982, p = 0.1563). The mean dose for the max measure was 3517 cGy for the
physical plan, 3422 cGy for the duo, and the lowest dose at 3229 cGy for the biological plan. See
table 4.
Liver
The V30 and mean constraints were both evaluated for each plan, as well as the
maximum dose received. The V30 and max proved to be statistically insignificant (p=0.207,
p=0.4949). The mean dose proved to be statistically significant, F(2.0, 28.0) = 20.211, p =
<0.0001. Mauchly’s test indicated sphericity assumed, χ²(2.0) = 0.194, p = 0.9076. Post hoc
analysis revealed the duo plan was lower than both the physical (t(14) = 6.0407, p = <0.0001)
and biological (t(14) = 1.8108, p = 0.0917). The mean dose to the physical plan was 1248 cGy,
1197 cGy for the biological, and the lowest dose of 1178 cGy for the duo plan. See table 5.
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Stomach
The V45, mean dose and max dose were all compared for the stomach. Results indicate no
statistical significance for either the V45 or max dose (p=0.7254, p=0.4949). The mean dose did
prove to be statistically significant, F(2.0, 28.0) = 11.0276, p = 0.0003. Mauchly’s test indicated
sphericity assumed (χ²(2.0) = 5.5738, p = 0.0616). A post hoc analysis was performed using a
paired sample t-test. Results show the duo plan was lower than both the physical (t(14) =
3.8081, p = 0.0019) and the biological plan (t(14) = 2.5189, p = 0.0246). The biological plan was
also lower than the physical plan (t(14) = 3.1129, p = 0.0076). The mean dose for the physical plan
was 2538 cGy, 2483 cGy for the biological, and 2421 cGy for the duo plan. See table 6.

Discussion
The goal of this study was to compare dose to organs at risk while using different
optimization techniques. For good measure, PTV coverage was also assessed. Physical
objectives, biological objectives, and a combination of the two were utilized to compare which
technique provided the best coverage of the PTV while also preserving the greatest amount of
healthy tissue.

Minimum coverage to the PTV was best achieved using the physical planning technique.
See figure 1. Although, while this was optimal for PTV coverage the physical planning
technique also yielded the greatest dose to nearby organs at risk. The physical plans also
provided the lowest max dose and global max dose between all 3 planning techniques. See table
1. The importance of PTV coverage is of utmost concern due to the recurrent nature of cancer
when microscopic disease remains left behind. If a plan achieves both acceptable PTV coverage
and lowest dose to nearby organs at risk, the plan may be considered optimal.
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While the use of gEUD objectives proved to be influential in lowering dose to the OARs
as prior research had suggested8, the homogeneity of the dose distribution as well as PTV
coverage was compromised. This may be due to the inherent power of the gEUD and the
indiscriminate nature of working on the mean of the isodose lines. Using only gEUDs to achieve
low dose to OARs created an inconsistent dose distribution as well as lack of overall plan
quality. This was an important finding to conclude due to the fact that while using only gEUD
objectives in the aim of sparing dose to OARs and healthy tissue was achieved, and is an
important goal of radiation therapy, it is equally as important to provide sufficient dose to kill to
the tumor volume to decrease risk of recurrence. So, while the lowered dose to each structure
was preferable, the conformality of dose was not.

Limitations and Future Research
Multiple limitations to this study were observed. Had the organs at risk been cropped out
of the PTV structure there may have been better dose control to OARs as well as a decrease in
the influence it had on PTV coverage and conformality. An attempt at lowering dose to a
structure located inside the PTV will inherently decrease coverage. Also, as time progressed the
planner acquired new techniques that may have impacted plan quality due to more experience
with planning. Furthermore, lack of investigation into the conformality index of each plan may
skewed the results.

A continuation of research would prove to be beneficial in regards to the conformality
index between the 3 plans. Also, further investigation into alpha values other than 1 and 40
should be conducted while used in conjunction with physical based upper values in the
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optimizer. Lastly, examination of a variation in treatment volumes used for the physical
constraints could prove to be impactful.

Conclusion
Overall, the plans that utilized both physical and biological constraints provided the
lowest dose to organs at risk as well as best conformality. While PTV coverage was not the
highest with the duo plan, it was still deemed acceptable in conjunction with other plan
parameters such as OAR dose as well as dose homogeneity. A physical upper constraint of 0% of
the organ volume receiving a maximum dose, as well as a gEUD constraint with an alpha value
of 1 provided the most optimal plans in pancreatic cancer treatment planning. A low priority
value on the gEUD (60-70) in conjunction with the upper value provided a gentle yet effective
way to control dose to nearby organs at risk without resulting in an unacceptable variation in
dose to planning target volume.

Generally, the research was found to be in accordance with the previous findings related
to dose variations. The results were in agreement with the Apinorasethkul study12, being that a
combination of uppers and a gEUD would provide a higher quality plan than using gEUDs
alone. It also verified the inherent power of the gEUD that the work of D Mihailidis et al
suggested10, although unlike the Mihailidis study the minimum dose to PTV did not remain
optimal. This may have been due to the proximity of the organs at risk to the planning target
volume. It also may be due to the fact that the organs at risk were not cropped out of the target
volume.
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Table 1. Dose Statistics
for PTV
Structure
PTV

Measure

Mauchly

Min

χ²(2.0) = 2.728,
p = 0.2556

Plan

Max

χ²(2.0) = 5.2447,
p = 0.0726

Global
Max

χ²(2.0) = 4.7592, p
= 0.0926

Mean

SE

Physical
Biological

90.18
86.56

1.3168
1.4857

Duo

85.54

1.7505

Physical
Biological

106.38
108.3933

0.2606
0.3653

Duo

107.6933

0.1626

Physical
Biological

106.3867
108.2933

0.2613
0.3492

Duo

107.6933

0.1626

Epsilon

F_test

Sphericity
assumed

F(2.0, 28.0) = 10.9041,
p = 0.0003

Sphericity
assumed

F(2.0, 28.0) = 17.95, p
= <0.0001

Sphericity
assumed

F(2.0, 28.0) = 16.6472,
p = <0.0001

Table 2. T-Test Post
Hoc Analysis For
PTV
Structure

Measure

Comparison

Mean_Diff

SE_Diff

T_Test

PTV

Min

Physical - Biological

3.62

0.8022

t(14) = 4.5125, p = 0.0005

Physical - Duo

4.64

1.0846

t(14) = 4.2782, p = 0.0008

Biological - Duo

1.02

1.2049

t(14) = 0.8465, p = 0.4115

Physical - Biological

-2.0133

0.4

Physical - Duo

-1.3133

0.2246

t(14) = -5.0335, p =
0.0002
t(14) = -5.8464, p =
0.0001
t(14) = 1.8792, p = 0.0812

Max

Global Max

Table 3. Dose Statistics for Small Bowel Max
Structure Measure
Mauchly
Small
Bowel

Max

χ²(2.0) = 4.8329, p = 0.0892

Biological - Duo

0.7

0.3725

Physical - Biological

-1.9067

0.3919

Physical - Duo

-1.3067

0.2273

Biological - Duo

0.6

0.3706

t(14) = -4.8655, p =
0.0002
t(14) = -5.7487, p =
0.0001
t(14) = 1.6191, p = 0.1277

Plan

Mean

SE

Epsilon

F_test

Physical

4608.3333

51.905

Sphericity assumed

F(2.0, 28.0) = 0.8873,
p = 0.423

Biological

4581.6

88.2157

Duo

4632.1333

72.3338
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Figure 1. PTV Bar Chart

Table 4. Dose Statistics for
Kidneys V18, Mean, Max

Structure
Right
Kidney

Measure
V18

χ²(2.0) = 0.0143, p =
0.9929

Mean

χ²(2.0) = 2.7614, p =
0.2514

Max

Left
Kidney

Mauchly

χ²(2.0) = 4.5199, p =
0.1044

V18

χ²(2.0) = 110.06, p = 0.0

Mean

χ²(2.0) = 1.3042, p =
0.521

Max

χ²(2.0) = 7.0365, p =
0.0297

Plan

Mean

SE

Physical
Biological

29.324
26.7033

5.6852
6.4601

Duo

25.39

6.0669

Physical

1345.3333

138.2356

Biological
Duo

1280.5333
1267.4

162.9567
163.6647

Physical
Biological

3503.2
3193.8667

258.4088
283.9441

Duo

3494.4

250.747

Physical
Biological
Duo

335.3953
18.8333
22.308

311.531
6.1532
6.5123

Physical

1222.3333

156.9226

Biological
Duo

1133.1333
1157.2

155.2448
175.6181

Physical
Biological

3517.4
3229.3333

315.1009
323.019

Duo

3422.5333

338.1329
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Epsilon

F_test

Sphericity assumed

F(2.0, 28.0) = 0.7613, p = 0.4765

Sphericity assumed

F(2.0, 28.0) = 0.8899, p = 0.422

Sphericity assumed

F(2.0, 28.0) = 8.2192, p = 0.0016

Greenhouse-Geisser Correction
(0.5001)

F(1.0001, 14.0015) = 1.0124, p =
0.3314

Sphericity assumed

F(2.0, 28.0) = 1.031, p = 0.3698

Greenhouse-Geisser Correction
(0.7052)

F(1.4104, 19.7463) = 3.9933, p =
0.0474

Table 5. Dose Statistics
for Liver V30, Mean, Max
Measure
V30

Mauchly

Plan

χ²(2.0) = 1.1507, p = 0.5625

Mean

Physical

8.6313

2.0698

Biological

8.4653

2.0509

Duo
Mean

Max

χ²(2.0) = 0.194, p = 0.9076

χ²(2.0) = 15.4663, p =
0.0004

SE

Physical

8.38

1.991

1248.4667

156.9931

Biological

1197.6

159.846

Duo

1178.2

156.4864

Physical

4491.6

145.1038

Biological

4426.4

191.8417

4513

142.6306

Duo

Epsilon

F_test

Sphericity assumed

F(2.0, 28.0) = 1.6671, p = 0.207

Sphericity assumed

F(2.0, 28.0) = 20.211, p = 0.0

Greenhouse-Geisser Correction (0.5897)

F(1.1795, 16.5124) = 1.9264, p =
0.1839

Table 6. Dose Statistics
for Stomach
Structure

Measure

Stomach

V45

Max

Mauchly
χ²(2.0) =
6.8308, p =
0.0329

χ²(2.0) =
12.8639, p =
0.0016

Plan

Mean

SE

Epsilon

Physical

23.2567

6.4575

Greenhouse-Geisser
Correction (0.7099)

Biological

23.5853

6.4191

Duo

23.6087

6.568

Physical

4667.4667

44.2522

Biological

4668.0667

80.0443

Duo

4698.1333

49.1653
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Greenhouse-Geisser
Correction (0.6142)

F_test
F(1.4197, 19.8763)
= 0.2235, p
= 0.7254

F(1.2283, 17.1964)
= 0.5694, p
= 0.4949
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